{"id":"tenecteplase-or-alteplase","safety":{"commonSideEffects":[{"rate":"0.6–1.3%","effect":"Bleeding (intracranial hemorrhage)"},{"rate":"5–10%","effect":"Bleeding (major extracranial)"},{"rate":null,"effect":"Reperfusion arrhythmias"},{"rate":null,"effect":"Hypotension"},{"rate":"<1%","effect":"Allergic reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Both drugs are serine proteases that bind to fibrin in blood clots and catalyze the conversion of plasminogen to plasmin, a potent fibrinolytic enzyme. Plasmin degrades the fibrin matrix that holds clots together, leading to clot dissolution. Tenecteplase is a genetically modified variant of alteplase with improved fibrin specificity and longer half-life, allowing for single-bolus dosing.","oneSentence":"Tenecteplase and alteplase are tissue plasminogen activators (tPA) that convert plasminogen to plasmin, which breaks down fibrin clots.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:11:38.865Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute ischemic stroke"},{"name":"Acute myocardial infarction (ST-elevation MI)"},{"name":"Pulmonary embolism"}]},"trialDetails":[{"nctId":"NCT07253181","phase":"PHASE3","title":"Tenecteplase Before Interhospital Transfer for EVT in Acute Anterior Circulation LVO at 4.5-24 Hours","status":"RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2026-01-06","conditions":"Acute Ischemic Stroke, Large Vessel Occlusion, Transportation of Patients","enrollment":572},{"nctId":"NCT07476898","phase":"PHASE3","title":"Precision Reperfusion Therapy for Disabling Minor Stroke With Large Vessel Occlusion Beyond Time Window","status":"NOT_YET_RECRUITING","sponsor":"First Hospital of China Medical University","startDate":"2026-03-01","conditions":"Stroke","enrollment":864},{"nctId":"NCT06018181","phase":"","title":"Outcomes After Intravenous Alteplase / Tenecteplase With or Without Shuxuetong Injection in Routine Clinical Practice","status":"COMPLETED","sponsor":"Dongzhimen Hospital, Beijing","startDate":"2023-09-28","conditions":"Ischemic Stroke, Acute","enrollment":2408},{"nctId":"NCT06241677","phase":"NA","title":"Intravenous Thrombolytic Therapy in Acute Ischemic Stroke Patients on DOAC","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2024-04-15","conditions":"CVA (Cerebrovascular Accident)","enrollment":260},{"nctId":"NCT05499832","phase":"PHASE3","title":"Safety and Efficacy of Intra-arterial Tenecteplase for Noncomplete Reperfusion of Intracranial Occlusions","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-03-21","conditions":"Ischemic Stroke","enrollment":156},{"nctId":"NCT06949228","phase":"PHASE2, PHASE3","title":"Adjunctive Intra-arterial Tenecteplase Following Mechanical Thrombectomy (ALLY) II Trial","status":"RECRUITING","sponsor":"ProMedica Health System","startDate":"2025-07-30","conditions":"Ischemic Stroke, Acute Disease","enrollment":132},{"nctId":"NCT07347626","phase":"PHASE3","title":"Eptifibatide for Extended Window Ischemic Stroke After Thrombolysis","status":"NOT_YET_RECRUITING","sponsor":"Xinqiao Hospital of Chongqing","startDate":"2026-03-01","conditions":"Acute Ischemic Stroke","enrollment":786},{"nctId":"NCT07271342","phase":"","title":"Observational RegIstry of Effectiveness and Safety of teNecTeplase in reAl worLd Settings in China","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2025-11-30","conditions":"Stroke","enrollment":10000},{"nctId":"NCT07318948","phase":"NA","title":"BALANCE Trial Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632","status":"NOT_YET_RECRUITING","sponsor":"Bo Wu","startDate":"2026-01-01","conditions":"Acute Ischemic Stroke","enrollment":1600},{"nctId":"NCT07208097","phase":"NA","title":"Stereotactic Thrombolysis With Tenecteplase for Supratentorial Intracerebral Hemorrhage","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-10-25","conditions":"Intracerebral Haemorrhage, Minimally Invasive Treatment","enrollment":768},{"nctId":"NCT05363397","phase":"PHASE2","title":"Safety and Tolerability of Adjunctive TBO-309 in Reperfusion for Stroke","status":"RECRUITING","sponsor":"The Florey Institute of Neuroscience and Mental Health","startDate":"2023-09-27","conditions":"Acute Ischemic Stroke","enrollment":80},{"nctId":"NCT06221371","phase":"PHASE3","title":"Endovascular Treatment With or Without Preceding Intravenous Tenecteplase (TNK) in Patients With Late-window acUte Ischemic Stroke Due to Middle Cerebral Artery Occlusion","status":"COMPLETED","sponsor":"Beijing Tiantan Hospital","startDate":"2024-01-25","conditions":"Ischemic Stroke, Acute, Thrombolysis, Endovascular Treatment","enrollment":391},{"nctId":"NCT06196320","phase":"PHASE3","title":"Tenecteplase Reperfusion Therapy in Acute Ischaemic Cerebrovascular Events-5","status":"COMPLETED","sponsor":"Beijing Tiantan Hospital","startDate":"2024-01-24","conditions":"Ischemic Stroke, Acute","enrollment":452},{"nctId":"NCT07047014","phase":"PHASE3","title":"Advancing Reperfusion Therapy for Ischemic Stroke (ARTS): Tenecteplase in Medium Vessel Occlusion (MeVO) for Acute Ischemic Stroke","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2025-07-30","conditions":"Stroke, Ischemic, Medium Vessel Occlusions","enrollment":596},{"nctId":"NCT06954155","phase":"PHASE3","title":"Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-BEYOND","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2025-05-30","conditions":"Stroke","enrollment":330},{"nctId":"NCT06320431","phase":"PHASE3","title":"ACT-GLOBAL THROMBOLYSIS (ACT-WHEN-001) Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632","status":"RECRUITING","sponsor":"University of Calgary","startDate":"2024-09-26","conditions":"Acute Ischemic Stroke AIS, Stroke Acute, Stroke, Acute, Stroke Ischemic","enrollment":4000},{"nctId":"NCT07168278","phase":"PHASE3","title":"Tenecteplase vs Medical Management in 4.5-24h LVO no Access to EVT","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of University of Science and Technology of China","startDate":"2025-11-01","conditions":"Acute Ischemic Stroke, Large Vessel Occlusion, Tenecteplase","enrollment":794},{"nctId":"NCT06878066","phase":"PHASE3","title":"Thrombolysis in Factor Xa-inhibitors Trial","status":"RECRUITING","sponsor":"Guri Hagberg","startDate":"2025-03-14","conditions":"Stroke, Stroke (in Patients With Atrial Fibrillation), Ischemic Stroke","enrollment":300},{"nctId":"NCT06801054","phase":"PHASE1","title":"Safety Of A Second Dose Of Tenecteplase In Selected Acute Ischemic Stroke Patients Not Responding To The First Dose","status":"NOT_YET_RECRUITING","sponsor":"Memorial Hermann Health System","startDate":"2025-07-01","conditions":"Acute Ischemic Stroke","enrollment":20},{"nctId":"NCT05199194","phase":"PHASE3","title":"Randomization to Endovascular Treatment Alone or Preceded by Systemic Thrombolysis With Tenecteplase in Ischemic Stroke","status":"RECRUITING","sponsor":"Hospital Moinhos de Vento","startDate":"2022-05-27","conditions":"Stroke, Ischemic, Stroke, Acute","enrollment":398},{"nctId":"NCT06571149","phase":"PHASE4","title":"Safety and Efficacy of Intravenous Thrombolysis in Patients With Ischemic Stroke and Direct Oral Anticoagulants Intake","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2025-03-14","conditions":"Ischemic Stroke","enrollment":906},{"nctId":"NCT06833827","phase":"NA","title":"'Thrombectomy in High-Risk Pulmonary Embolism - Device Versus Thrombolysis Netherlands': TORPEDO-NL","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-02","conditions":"Pulmonary Embolism Acute","enrollment":111},{"nctId":"NCT04454788","phase":"PHASE3","title":"Extending the Time Window for Tenecteplase by Effective Reperfusion in Patients with Large Vessel Occlusion","status":"TERMINATED","sponsor":"University of Melbourne","startDate":"2020-08-01","conditions":"Ischemic Stroke","enrollment":242},{"nctId":"NCT02777580","phase":"PHASE4","title":"STrategic Reperfusion in Elderly Patients Early After Myocardial Infarction","status":"COMPLETED","sponsor":"KU Leuven","startDate":"2017-08-01","conditions":"Myocardial Infarction","enrollment":609},{"nctId":"NCT05827042","phase":"PHASE3","title":"Endovascular Thrombectomy Alone Versus Intravenous Thrombolysis Plus Thrombectomy on Acute Basilar Artery Occlusion","status":"RECRUITING","sponsor":"The First Affiliated Hospital of University of Science and Technology of China","startDate":"2023-05-09","conditions":"Basilar Artery Occlusion, Acute Cerebrovascular Accident, Stroke Due to Basilar Artery Occlusion","enrollment":338},{"nctId":"NCT06034847","phase":"NA","title":"Treatment of Persistent Distal Occlusion After Successful Proximal Recanalization in Thrombectomy","status":"NOT_YET_RECRUITING","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2024-09","conditions":"Stroke, Acute Thrombotic","enrollment":300},{"nctId":"NCT05141305","phase":"PHASE3","title":"Teneteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-III","status":"COMPLETED","sponsor":"Beijing Tiantan Hospital","startDate":"2022-01-19","conditions":"Ischemic Stroke, Acute","enrollment":516},{"nctId":"NCT05684172","phase":"PHASE2, PHASE3","title":"Intra-arterial TNK Following Endovascular Thrombectomy in Patients With Large Vessel Occlusion of Posterior Circulation","status":"COMPLETED","sponsor":"The First Affiliated Hospital of University of Science and Technology of China","startDate":"2023-01-24","conditions":"Acute Ischemic Stroke, Intracranial Artery Occlusion, Endovascular Thrombectomy","enrollment":208},{"nctId":"NCT05900674","phase":"PHASE2","title":"Endovascular Stroke Treatment And Reteplase Protocol","status":"WITHDRAWN","sponsor":"Zeenat Qureshi Stroke Institute","startDate":"2023-07","conditions":"Ischemic Stroke","enrollment":""},{"nctId":"NCT05105633","phase":"PHASE2, PHASE3","title":"Extending the Time Window for Tenecteplase by Recanalization of Basilar Artery Occlusion in Posterior Circulation Stroke","status":"RECRUITING","sponsor":"University of Melbourne","startDate":"2021-11-29","conditions":"Basilar Artery Occlusion","enrollment":688},{"nctId":"NCT05809921","phase":"","title":"Dual IntraVenous Thrombolysis Approach (DIVA) in Patients With Medium-vessel-occlusion Strokes: a Retrospective Study","status":"COMPLETED","sponsor":"Centre Hospitalier Sud Francilien","startDate":"2023-05-17","conditions":"Acute Ischemic Stroke Due to Medium-vessel-occlusion","enrollment":294},{"nctId":"NCT05733507","phase":"","title":"Tirofiban Plus Intravenous Thrombolysis in Acute Anterior Choroidal Infarction or Paramedian Pontine Infarction","status":"COMPLETED","sponsor":"Centre Hospitalier Sud Francilien","startDate":"2023-04-03","conditions":"Acute Anterior Choroidal Infarction (ACI), Paramedian Pontine Infarction (IPP)","enrollment":48},{"nctId":"NCT05634382","phase":"PHASE3","title":"Endovascular Thrombectomy With and Without Intravenous Thrombolysis in Extended Time Window","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-12-03","conditions":"Stroke, Acute Ischemic","enrollment":222},{"nctId":"NCT04797013","phase":"PHASE3","title":"Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-Ⅱ","status":"COMPLETED","sponsor":"Beijing Tiantan Hospital","startDate":"2021-06-12","conditions":"Acute Ischemic Stroke","enrollment":1430},{"nctId":"NCT05626972","phase":"PHASE3","title":"Tenecteplase Compared to Alteplase for Patients With Large Vesel Oclusion Suspicion Before Thrombectomy","status":"UNKNOWN","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","startDate":"2022-05-27","conditions":"Acute Ischemic Stroke","enrollment":500},{"nctId":"NCT04558125","phase":"PHASE4","title":"Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism","status":"TERMINATED","sponsor":"Cedars-Sinai Medical Center","startDate":"2020-09-08","conditions":"Pulmonary Embolism, COVID","enrollment":2},{"nctId":"NCT01654445","phase":"PHASE2","title":"TNK-tPA Evaluation for Minor Ischemic Stroke With Proven Occlusion","status":"COMPLETED","sponsor":"University of Calgary","startDate":"2012-07","conditions":"Ischemic Stroke","enrollment":50},{"nctId":"NCT00623623","phase":"PHASE3","title":"STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-03-01","conditions":"Myocardial Infarction","enrollment":1899},{"nctId":"NCT02338466","phase":"PHASE2","title":"Superiority of Rt-PA + Tenecteplase in Comparison With Rt-PA Only in Proximal Middle Cerebral Artery Occlusion","status":"WITHDRAWN","sponsor":"University Hospital Center of Martinique","startDate":"2016-07","conditions":"Nervous System Disorders, Cerebral Artery","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4437,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Tenecteplase or Alteplase","genericName":"Tenecteplase or Alteplase","companyName":"Insel Gruppe AG, University Hospital Bern","companyId":"insel-gruppe-ag-university-hospital-bern","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tenecteplase and alteplase are tissue plasminogen activators (tPA) that convert plasminogen to plasmin, which breaks down fibrin clots. Used for Acute ischemic stroke, Acute myocardial infarction (ST-elevation MI), Pulmonary embolism.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}